2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
12/13/17Nuvectra Achieves 1,000th Algovita® SCS System Implantation in U.S.
PLANO, Texas, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company’s Algovita® Spinal Cord Stimulation (SCS) system has now been implanted in 1,000 patients across the U.S. seeking non-pharmaceutical relief from chronic pain. The milestone procedure was performed on a SCS patient by Giancarlo Barolat, MD, Neuromodulation Medical Director at Presbyterian/St. Luke’s Medical Center located in Denver, Colo... 
Printer Friendly Version
11/15/17Nuvectra to Present at the 29th Annual Piper Jaffray Healthcare Conference
PLANO, Texas, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference.     Event: 29th Annual Piper Jaffray Healthcare Conference   Date: Tuesday, November 28, 2017   ... 
Printer Friendly Version
11/06/17Nuvectra to Present at the Stifel 2017 Healthcare Conference
PLANO, Texas, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to participate at the Stifel 2017 Healthcare Conference in New York, NY.       Event:    Stifel 2017 Healthcare Conference Date:   Tuesday, November 14, 20... 
Printer Friendly Version
11/01/17Nuvectra™ Reports Third Quarter 2017 Financial Results
Record Quarterly Algovita Revenues, Increasing to $6.3 Million PLANO, Texas, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the third quarter ended September 30, 2017. Highlights Record consolidated revenues of $7.6 million Virtis™ CE Mark approval anticipated in Q1 2018. On track for FDA approval with an anticipated commercial launch in the U.S. in the back half of 2018 Enter... 
Printer Friendly Version
10/24/17Nuvectra to Report Third Quarter 2017 Financial Results on November 1, 2017
PLANO, Texas, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2017 on Wednesday, November 1, 2017 after market close. Nuvectra will hold a conference call on Wednesday, November 1, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. ... 
Printer Friendly Version
09/11/17First Spinal Cord Stimulator Implant Placed in Northern California by Dr. Goldthwaite Brings Pain Relief and Reduces Opioid Use for Local Injured Veteran
PLANO, Texas, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Noel Goldthwaite, MD, senior surgeon and founding member at SpineCare Medical Group, Inc., is the first physician in northern California to implant Nuvectra’s Algovita® Spinal Cord Stimulation System, which successfully treated a local injured veteran’s chronic pain and led to his significant reduction in opioid use. The Nuvectra Algovita SCS System is a powerful and versatile spinal cord stimulation system that includes the smallest patient con... 
Printer Friendly Version
08/30/17Nuvectra to Participate in Morgan Stanley Global Healthcare Conference
PLANO, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & CFO, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York, NY. Event:       Morgan Stanley Global Healthcare Conference Date:         Monday, September 11, 2017 The Company will be participating in one-on-one investor m... 
Printer Friendly Version
08/08/17Nuvectra™ Reports Second Quarter 2017 Financial Results
Record Quarterly Algovita® Revenues, Increasing 62% Sequentially PLANO, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the second quarter ended June 30, 2017. Highlights Record consolidated revenues of $7.2 million, including total Algovita® sales of $5.5 million Completed FDA regulatory submission for full-body MRI-conditional approval for the Algovita SCS system On tr... 
Printer Friendly Version
07/28/17Nuvectra to Present at the Wedbush PacGrow Healthcare Conference
PLANO, Texas, July 28, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference. Event:       Wedbush PacGrow Healthcare Conference Format:     Present... 
Printer Friendly Version
07/25/17Nuvectra to Report Second Quarter 2017 Financial Results on August 8, 2017
PLANO, Texas, July 25, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after market close. Nuvectra will hold a conference call on Tuesday, August 8, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conferen... 
Printer Friendly Version
06/21/17Nuvectra Files Regulatory Submission with FDA for Algovita® MRI-Conditional Approval
PLANO, Texas, June 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MRI-conditional approval for the Company’s Algovita SCS system. Scott Drees, Chief Executive Officer, commented, “This submission to the FDA represents our continued commitment to the advancement of the Algovita system. The addition of a full bo... 
Printer Friendly Version
05/09/17Nuvectra™ Reports First Quarter 2017 Financial Results
PLANO, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2017. Highlights Record total revenues of $5.0 million, including total Algovita sales of $3.4 million U.S. commercial team building momentum with new and existing customers Remain on track with the Virtis U.S. and European regulatory approval timelines Scott Drees, CEO, said, “We c... 
Printer Friendly Version
05/03/17Nuvectra to Present at the 18th Annual B. Riley Co. Investor Conference
PLANO, Texas, May 03, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 18th Annual B. Riley Co. Investor Conference in Santa Monica, CA. Management will also be available for one-on-one meetings at the conference. Event:       18th Annual B. Riley Co. Investor Conference Fo... 
Printer Friendly Version
04/27/17Nuvectra to Report First Quarter 2017 Financial Results on May 9, 2017
PLANO, Texas, April 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2017 on Tuesday, May 9, 2017 after market close. Nuvectra will hold a conference call on Tuesday, May 9, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID... 
Printer Friendly Version
03/27/17Nuvectra Announces Cowen & Company Hosted Physician Panel on Spinal Cord Stimulation on March 29, 2017
Investor event will feature Q&A on SCS market and Nuvectra’s Algovita system PLANO, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Cowen and Company and The Ruth Group are hosting a physician panel on the spinal cord stimulation market and the Algovita system. The event will feature discussions with Jeffery Rowe, MD, and Brian Bannister, MD, and will be moderated by Cowen medical technology anal... 
Printer Friendly Version
03/07/17Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results
PLANO, Texas, March 07, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 30, 2016. Recent Highlights Completed FDA Premarket Approval and TUV CE mark submissions for Virtis™ Executed direct supply agreement with Minnetronix for Algovita® external devices Extended availability of the final two tranches of the $45 million debt facility U.S.... 
Printer Friendly Version
03/06/17Nuvectra to Present at the 29th Annual ROTH Conference
PLANO, Texas, March 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th Annual ROTH Conference in Dana Point, CA. Management will also be available for one-on-one meetings at the conference. Event:  29th Annual ROTH Conference Date:  Monday, March 13, 2017 Time:  1:0... 
Printer Friendly Version
03/01/17Nuvectra to Present at the Cowen and Company 37th Annual Health Care Conference
PLANO, Texas, March 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference. Event: Cowen and Company 37th Annual Health Care Conferen... 
Printer Friendly Version
02/21/17Nuvectra to Report Fourth Quarter 2016 Financial Results on March 7, 2017
PLANO, Texas, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter ended December 30, 2016 on Tuesday, March 7, 2017 before the market open. Nuvectra will hold a conference call on Tuesday, March 7, 2017 at 8:30am ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The co... 
Printer Friendly Version
02/14/17Nuvectra Extends Timeline of Existing Credit Facility
PLANO, Texas, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with the lenders of its $45 million credit facility, Silicon Valley Bank and Oxford Finance, to extend the availability of the final two tranches of the facility. On March 18, 2016, the Company entered into a loan agreement with Silicon Valley Bank and Oxford Finance consisting of a $40.0 million term loan credit faci... 
Printer Friendly Version
02/06/17Nuvectra to Present at the Leerink Partners 6th Annual Global Healthcare Conference
PLANO, Texas, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to conduct a fireside chat presentation at the Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference. Event: L... 
Printer Friendly Version
02/01/17Nuvectra Files Regulatory Submissions for FDA and CE Mark Approvals of the Virtis™ Sacral Nerve Stimulation (SNS) System
PLANO, Texas, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed regulatory submissions with the U.S. Food and Drug Administration (FDA) and CE Mark authorities for Virtis™, the Company’s sacral nerve stimulation (SNS) system for the treatment of chronic urinary retention and the symptoms of overactive bladder. Scott Drees, Chief Executive Officer, commented, “We are excited to announce that we h... 
Printer Friendly Version
01/17/17Nuvectra Receives Frost & Sullivan’s New Product Innovation Award for Its Algovita® SCS System
PLANO, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, has recently been named recipient of the Frost & Sullivan North American New Product Innovation Award for its leadership in the spinal cord stimulation (SCS) market. Frost & Sullivan recognizes Nuvectra for the organization’s commitment to advancing next-generation neurostimulation technologies through its Algovita® Spinal Cord Stimulation System. Each year,... 
Printer Friendly Version
01/05/17Frost & Sullivan Recognizes Nuvectra's Pioneering Spinal Cord Stimulation Product for Chronic Pain Management
The intelligent and innovative Algovita® SCS System found strong favor among physicians and patients SANTA CLARA, Calif., Jan. 5, 2017 /PRNewswire/ -- Based on its recent analysis of the spinal cord stimulation (SCS) market, Frost & Sullivan recognizes Nuvectra with the 2017 North American New Product Innovation Award for its flagship product, the Algovita® SCS System. SCS is fast becoming the non-drug alternative for chronic pain conditions, and Nuvectra's commitment to advancing next... 
Printer Friendly Version